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T Cell Division and Death Are Segregated by
Mutation of TCR Chain Constant Domains
ways, which result in the death of some of the expanding
cells (Lenardo et al., 1999).
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Matsui et al. have demonstrated that after CD3 stimula-
tion, NF-B regulates murine FasL transcription by co-
operative interactions with AP-1 and Egr (Matsui et al.,
Summary 1998, 2000). This, together with other studies, suggests
that NF-B is an important factor controlling FasL induc-
We have studied the role of the T cell receptor (TCR) tion in T cells (Hsu et al., 1999; Kasibhatla et al., 1999;
 chain transmembrane and cytoplasmic domains Teixeiro et al., 1999).
(TM/Cyto) in T cell signaling. Upon antigen stimula- NF-B is induced by different receptor-generated sig-
tion, T lymphocytes expressing a TCR with mutant nals that converge by phosphorylating and activating
TM and Cyto domains accumulate in large numbers the IKK complex (Rothwarf and Karin, 1999). Recently,
and are specifically defective in undergoing activation- two signaling adaptors, Carma-1 and Bcl-10, have been
induced cell death (AICD). The mutant TCR poorly re- shown to link the TCR and PKC to the activation of the
cruits the protein adaptor Carma-1 and is subse- IKK complex (Gaide et al., 2002; Jun and Goodnow,
quently impaired in activating NF-B. This signaling 2003; Pomerantz et al., 2002; Ruland et al., 2001; Wang
defect leads to a reduced expression of Fas ligand et al., 2002). Upon TCR engagement, Carma-1 is associ-
(FasL) and to a reduction in AICD. These  chain do- ated with the TCR, allowing the recruitment of Bcl-10
mains are involved in discriminating cell division and to the membrane. This, together with PKC activation,
apoptosis. leads to activation of the IKK complex and subsequent
phosphorylation and degradation of the NF-B inhibitor
IB, resulting in NF-B activation (Che et al., 2004;Introduction
Egawa et al., 2003; Gaide et al., 2002; Jun and Goodnow,
2003; Thome, 2004; Wang et al., 2002, 2004; Zhou etSuccessful T cell responses depend on the expansion
al., 2004).
of a small number of T lymphocytes with receptors spe-
T cells initiate effector responses in a hierarchical
cific for the immunizing antigen; these antigen-specific
manner (Itoh and Germain, 1997; Valitutti et al., 1996),
T cells are recruited from a large pool of T cells with but the mechanism underlying this signaling hierarchy
diverse receptor specificities. Antigen-stimulated T cells is not completely understood. Since stimulation through
proliferate rapidly and have been observed to divide the TCR is critical to both T cell proliferation and T cell
every 4 to 5 hr (Kurts et al., 1997). Unlimited T cell expan- apoptosis, one important issue is whether proliferation
sion would exclude nonproliferating T cells from the and apoptosis are mediated by distinct or related TCR
population and reduce the diversity of the T cell reper- signals. Relevant to this point is the finding that some
toire. To limit the total number of antigen-stimulated antigenic peptide ligands stimulate apoptosis, but not
T cells, dividing T cells activate apoptotic signaling path- cytokine production, in a T cell clone (Combadiere et
al., 1998). Furthermore, Jurkat cells expressing a TCR
chain with a point mutation in the transmembrane (TM)*Correspondence: ed.palmer@unibas.ch
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domain are able to secrete normal levels of IL-2 but (see Supplemental Figure S1 at http://www.immunity.
com/cgi/content/full/21/4/515/DC1/).show a defect in AICD (Rodriguez-Tarduchy et al., 1996).
While this indicates that the signals for apoptosis and In both wild-type and mutant Rag-2/ mice express-
ing the positive selecting ligand, I-Ab, a similarly highcytokine expression may be distinct, it does not address
the relationship between proliferative and apoptotic sig- percentage of lymph node cells bear the transgenic TCR
and CD4 (78% versus 86%). However, mice expressingnals originating from the TCR.
We gained some insight into this issue by generating the mutant receptor have 2-fold more TCR, CD48
lymph node T cells compared to mice expressing thea mutation in the TCR chain transmembrane and cyto-
solic (TM/Cyto) domains. Transgenic mice expressing wild-type TCR (9.4  2.5  106 wild-type versus 21.3 
6.6  106 mutant T cells) (Figure 1C). In addition, thethe mutant receptor displayed a lymphoproliferative
phenotype. The defect was not due to an increased rate transgenic mice were crossed onto B6.C.H-2-bm12,
Rag-2/ mice, which express the negative selectingof cell division but rather to a defect in T cell apoptosis.
The finding of such a mutant indicates that the TCR- ligand I-Abm12 for this receptor. In both strains, few TCR,
CD48 lymph node T cells were found, indicating thatmediated signals for cell division and apoptosis can
be segregated. both wild-type and mutant T cells are negatively se-
lected (Figure 1C). Furthermore, analysis of thymocyte
populations and maturation specific surface markersResults
shows that thymic selection is intact inTM/Cyto mutant
transgenic mice (data not shown).Mutation of the TCR Chain Transmembrane
and Cytoplasmic Domains
Among the constant domains of the TCRheterodimer, Exaggerated Proliferative Response in Mutant T Cells
Proliferative responses of wild-type and mutant T cellsthe TM domain has been highly conserved during evo-
lution. Interestingly, this domain diverged from the ho- to antigens were studied in vitro. Lymph node T cells
expressing the mutant receptor proliferated more vigor-mologous TCR	 chain TM domain 400 million years
ago. To assess the role of TM domain in T cell activa- ously in response to the MHC-encoded antigens I-Abm12
(Figure 2A) and I-Ad (data not shown) and the superanti-tion, we generated hybridomas expressing mutant 
chain TCRs. We used cDNAs encoding the  (V2) and gens Mtv-7 (Figure 2B) and SEB (data not shown; Pet-
ersen et al., 2004) than wild-type T cells. In analogous chain (V8.1/D1/J1.1) from the 3bbm74 TCR that is
reactive to the MHC-encoded alloantigen I-Abm12 and experiments performed in the presence of saturating
amounts of IL-2, similar differences were observed, im-Mtv-7 and Staphylococcus Enterotoxin B (SEB) super-
antigens (Backstrom et al., 1998; DiGiusto and Palmer, plying that the enhanced proliferation of the mutant
T cells is not directly related to IL-2 production (data1994). We designed two chimeric TCR  chains: the
TM/Cyto mutant construct encodes a mutant TCR not shown).
To ensure that this phenotype was not a particularchain, where the TCRTM domain and the TCR cyto-
plasmic tail have been substituted with homologous se- feature of the specificity of the 3bbm74 transgenic TCR,
we generated mice transgenic only for thechain, whichquences from C	1; and the Cyto mutant construct,
where only the cytoplasmic tail has been replaced with express TCRs comprised of either the wild-type or the
mutant TM/Cyto chain together with endogenous C	1 sequences (Figure 1A). Wild-type and mutant 
chain cDNAs, along with the wild-type 3bbm74 V2 chains. As with mice expressing the mutant 3bbm74 
receptor, transgenic mice expressing the mutant  chaincDNA, were transduced into the T cell hybridoma, 58
/ (Backstrom et al., 1996). All hybridomas expressed contain more peripheral T cells (27.4  5.8  106 wild-
type versus 40.2  6.1  106 mutant T cells per mouse).similar amounts of surface TCR (data not shown). When
tested for IL-2 or IL-3 production, TM/Cyto mutant The diversity of V domains expressed is also similar in
the two strains (data not shown). Since both transgenichybridoma cells were 10- to 100-fold more responsive
to increasing doses of SEB than T cell hybridomas ex-  chains encode the identical V8.1DJ region, the
corresponding T cells are responsive to SEB. Similar topressing the wild-type TCR (Figure 1B and Petersen
et al. [2004]). T cell hybridomas expressing the control mutant 3bbm74 T cells (Figures 2A and 2B), T lympho-
cytes expressing the mutant TM/Cyto chain proliferateCyto mutant were similar to hybrids expressing the
wild-type receptor in terms of their reactivity to SEB more than T cells expressing the wild-type  chain (Fig-
ure 2C). Therefore, the enhanced proliferation of the(Figure 1B), suggesting that the mutation of the TM
domain accounts for the hyperreactive phenotype of the mutant T cells is a function of the mutant TM/Cyto
chain and not a peculiarity of the 3bbm74  receptor.mutant TM/Cyto hybridoma.
Transgenic mice expressing the 3bbm74 wild-type As T cells require a period of continuous antigen expo-
sure to commit to activation, we considered the possibil-(Backstrom et al., 1998) and TM/Cyto mutant receptors
were generated and crossed to B6.Rag-2/ mice to ity that mutant T cells might require less time in terms of
antigen exposure to commit to a proliferative responseensure that no endogenous TCRs would be coex-
pressed. Lymph node cells from mice expressing the (Iezzi et al., 1999). To test this idea, we analyzed prolifer-
ation of responding T cells in the presence of APCswild-type or mutant receptors were analyzed by flow
cytometry for TCR and CD4 coreceptor expression (Fig- expressing I-Abm12. In these cultures, antigen presenta-
tion was terminated by adding an I-Abm12-blocking mAbure 1C). Lymph node T cells from both strains express
equivalent amounts of surface TCR (Figure 1D). Immu- (M5/114) at different time points. Naive peripheral T cells
from wild-type and mutant mice required at least 24 hr ofnoprecipitation assays showed that all TCR and CD3
subunits are present in the mutant TCR/CD3 complex continuous antigen exposure to commit to proliferation
TCR Constant Domains Control AICD
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Figure 1. Hybridomas and Peripheral T Cells from Transgenic Mice Expressing TM/Cyto Mutant TCR
(A) C-terminal amino acid sequences of wild-type and mutant  chains. Sequences are depicted beginning with the Cys, which forms the
interchain disulfide bond. Amino acids within the rectangles are derived from homologous regions of the murine TCR 	 chain (C	1).
(B) Responses of T cell hybridomas expressing the wild-type  chain along with a wild-type or a mutant  chain cultured with DAP. 3 APCs
pulsed with increasing concentrations of the Staphylococcal superantigen, SEB, overnight as previously described (Backstrom et al., 1996).
The data are representative of six experiments.
(C) Lymph node cells from B6 I-Ab, Rag-2/, or B6 I-Abm12, Rag-2/ mice expressing the wild-type or  TM/Cyto mutant TCR were stained
with anti-V2 and anti-CD4 mAbs. The number in the upper right quadrant indicates the percentage of CD4 T cells. The mean number of
CD4 T cells isolated from each strain (n 
 12) is indicated in each panel.
(D) Lymph node cells of B6.Rag-2/ TCR-transgenic mice were harvested and stained for the transgenic  chain with mAb anti-V2. TCR
expression on wild-type and mutant T cells is indicated by the gray and black histograms, respectively.
(Figure 2D). When exposed to antigen between 24 and tween ex vivo T cells and transformed hybridomas.
Taken together, the enhanced proliferation of mutant48 hr, T cells from both strains proliferated to a similar
extent. However, when these cells were exposed to anti- T cells is neither due to enhanced IL-2 secretion nor IL-
2R expression.gen for more than 48 hr, the mutant T cells underwent
an enhanced proliferation, while the wild-type cells con-
tinued to proliferate minimally (Figure 2D). These data Accumulation of Mutant T Cells Is Not Due
suggest that the increased proliferation of the mutant to Accelerated Cell Division
T cells is not due to a shortened commitment time to pro- For assessment of proliferative responses in vivo, pe-
liferate. ripheral T cells expressing the wild-type or the mutant
receptor were labeled with CFSE and adoptively trans-
ferred into T cell-deficient, B6.Rag-2/ mice, which ex-Normal Secretion of IL-2 and Expression
of Early Activation Markers press the alloantigen I-Abm12 (Figure 3A). The transferred
wild-type and mutant T cells did not proliferate on dayLymph node T cells were stimulated with I-Abm12-express-
ing APCs and the kinetics of CD69 and CD25 upregula- 1 but did proliferate on days 2 and 3 after transfer. On
each day, wild-type and mutant T cells underwent ation were measured. Wild-type and mutant T cells dis-
play similar CD69 and CD25 induction kinetics (Figures similar number of cell divisions (Figure 3A). However, the
number of recovered cells was dramatically increased in2E and 2F), indicating that many activation events are
similar between wild-type and mutant T cells. Further- the animals receiving mutant T cells. Three days after
transfer, 0.26  106 wild-type T cells were recoveredmore, wild-type and mutant T cells secrete comparable
amounts of IL-2 (Figure 2G). It is interesting that wild- from the spleens of B6.Rag-2/, I-Abm12 mice compared
to 4.2 106 mutant T cells, representing a 15-fold differ-type and mutant T cells secrete similar amounts of IL-2,
whereas mutant hybridoma cells clearly secrete more IL-2 ence (Figure 3B). Four days after transfer, 0.46  106
wild-type T cells were recovered from the lymph nodesthan their wild-type counterparts (Figure 1B). The reason
for this is unknown but may reflect the difference be- of B6.Rag-2/, I-Abm12 mice compared to 12.2  106
Immunity
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Figure 2. TM/Cyto Mutant T Cells Show an Enhanced Proliferative Response but Normal Expression of CD69, CD25, and IL-2 Secretion
(A and B) Mixed leukocytes cultures were initiated between 2  105 responder lymph nodes from B6 I-Ab, Rag-2/ transgenic mice expressing
the wild-type () or TM/Cyto mutant () TCRs and titrated numbers of irradiated stimulator spleen cells from (A) B6 I-Abm12, Rag-2/ mice
or (B) Mtv-7 CBA/J mice.
(C) Proliferative response of lymph node T cells from B6 mice expressing the transgenic wild-type  chain () TM/Cyto mutant  chain ()
along with endogenous  chains was assayed by culturing lymph node T cells from these mice with irradiated APCs and different doses of
SEB as in (A).
(D) Cultures of wild-type () and mutant () T cells with APCs expressing the I-Abm12 antigen were initiated and at various times; the stimulation
was terminated by adding a mAb (M5/114), which bound to the class II MHC molecule, I-Abm12, and prevented further T cell stimulation. All
cultures were maintained for 96 hr and pulsed with 3H thymidine for the last 12 hr.
(E and F) T cells expressing the wild-type or TM/Cyto mutant TCR were cultured with splenocytes bearing the I-Abm12 antigen. At various
time points, the expression of CD69 and CD25 on the responding wild-type () or TM/Cyto mutant () T cells was determined by flow cytometry.
(G) Wild-type () and TM/Cyto mutant () T cells were cultured as in (E), and IL-2 secretion was determined at the indicated times by flow
cytometry. There was no IL-2 response to stimulator cells from B6 (I-Ab) mice. The data in Figure 2 are representative of at least three experiments.
mutant T cells, a 25-fold difference (Figure 3C). There- the induction of p73 (Irwin et al., 2000), wild-type and
mutant cells showed a difference in p73 expression asfore, wild-type and mutant T cells divide at similar rates;
nevertheless, significantly more mutant cells accumu- well (Figure 4B). The expression of the antiapoptotic
proteins Bcl-2 and Bcl-XL (Marsden and Strasser, 2003)late during the proliferative phase.
are similar in both types of T cells (Figure 4B).
The status of the apoptotic machinery was also evalu-Mutant T Cells Have a Defect in AICD
We considered whether the striking increase in mutant ated. Wild-type and mutant T cells were stimulated with
a variety of agents known to induce apoptosis: actino-T cell accumulation could be explained by a defect in
AICD. The fraction of T cells undergoing apoptosis dur- mycin D, ionomycin, ceramide, staurosporine, etopo-
side, and 	-irradiation. Wild-type and mutant T cellsing the proliferative response to I-Abm12 was determined
by staining the antigen-stimulated T cells with Annexin undergo apoptosis to a similar extent with all the agents
tested including PMA/ionomycin, which bypasses theV. The data in Figure 4A show that throughout the entire
proliferative response, a smaller fraction of mutant TCR (Figure 4C). Fas-mediated apoptosis is induced
similarly in both wild-type and mutant T cells (Figure 4C).T cells undergo apoptosis compared to wild-type T cells.
Since FasL is the principal death cytokine involved in Cell death in these experiments was mediated mainly by
Fas/FasL, because apoptosis was substantially inhib-the apoptosis of cycling CD4T cells (Sytwu et al., 1996),
the responding T cells were assayed for the expression ited in both wild-type and mutant T cells in the presence
of reagents that block FasL (data not shown). Theseof surface FasL. Mutant T cells expressed 2-fold less
FasL than wild-type T cells (Figure 4B), whereas Fas data support the idea that TCR-mediated signals are
responsible for the impairment of AICD in the mutantreceptor expression is equivalent in both cell types (Fig-
ure 4B). T cells.
Additionally, we analyzed the expression of two tran-
scription factors, E2F-1 and p73, that have been linked TM/Cyto Mutant TCR Is Able to Discriminate
between Cell Division and AICDto AICD (Lissy et al., 2000). As shown in Figure 4B,
mutant T cells expressed approximately 2-fold less The availability of the I-Abm12 alloantigen was titrated
by adding increasing amounts of 3JP, a monoclonalE2F-1 than wild-type cells. Since E2F-1 contributes to
TCR Constant Domains Control AICD
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Figure 3. Proliferative TM/Cyto Mutant
Cells Accumulate In Vivo
(A) Transferred wild-type and mutant T cells
divide at similar rate. Wild-type and mutant
T cells were isolated, labeled with carboxy-
fluorescein diacetate succinimidyl ester (CFSE),
and injected intravenously into B6 I-Abm12,
Rag-2/ mice, which express the I-Abm12 anti-
gen recognized by the transgenic T cells. On
successive days after the i.v. injection of wild-
type () or mutant () T cells, spleens and
lymph nodes of recipient mice were har-
vested, and proliferation of the injected
T cells was analyzed by flow cytometry.
(B and C) Cells were recovered from the (B)
spleens and (C) lymph nodes of recipient
mice. T cells were delineated by staining with
antibodies anti-V2 and anti-CD4. The num-
ber of wild-type () and TM/Cyto mutant ()
transgenic T cells recovered on successive
days after adoptive transfer is shown. The
data are representative of three experiments.
antibody that binds to I-Abm12 and blocks the 3bbm74 Furthermore, they illustrate that the signaling defect
spares proliferation and IL-2 secretion and affects theT cell response (Backstrom et al., 1998) to determine
whether the defect in AICD was evident across a range induction of AICD.
of antigen concentrations. Under conditions of titrated
I-Abm12 availability, T cell proliferation, IL-2 secretion, and Analysis of Signaling Pathways in Mutant T Cells
TCR stimulation of wild-type and mutant cells revealedAICD were examined (Figure 5). At all antigen doses,
wild-type and mutant T cells show an equivalent degree no significant differences in the phosphorylation of CD3
and  chains (Figure 6A). Because several reports haveof proliferation based on their CFSE profiles (Figure 5A).
The division index (defined by the number of T cells demonstrated that Ca2 flux, ERK, JNK, and NF-B are
significant in the activation of FasL promoter (Kavurmaentering cell division and the average number of cell
divisions they undergo) is the same for wild-type and and Khachigian, 2003), these signaling pathways were
also examined. Stimulated wild-type and mutant T cellsmutant T cells at all antigen doses (Figure 5B). Both
types of T cells secrete similar amounts of IL-2, although exhibit similar levels of Ca2 mobilization as well as ERK
and JNK activation (Figures 6B and 6C). However, mu-mutant cells secrete more of this cytokine at some anti-
gen doses (Figure 5C). In contrast, at all antigen doses tant T cells are defective in phosphorylating and degrad-
ing the NF-B inhibitor IB. TCR-induced IB phos-that induce T cell death over background levels, a signifi-
cantly lower fraction of mutant T cells undergo AICD phorylation is decreased in mutant cells 3-fold, which
probably leads to a delayed IB degradation in thethan do wild-type T cells (Figure 5D). Moreover, similar
results were obtained in the presence of saturating mutant T cells (Figure 6D). In wild-type T cells, most of
the IB is degraded after 15 min of stimulation (20%amounts of exogenous IL-2 (data not shown). These
experiments rule out the possibility that mutant T cells remaining), but in mutant T cells, IB begins to be
degraded only after 60 min (Figure 6D). Therefore, theexhibit a defect in AICD only at a single antigen dose.
Immunity
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Figure 4. Defective AICD in TM/Cyto Mu-
tant T Cells
(A) Lymph node T cells from wild-type ()
and mutant () transgenic mice were cultured
with I-Abm12-expressing APCs for 4 days. Each
day, apoptotic T cells were detected by stain-
ing with Annexin V.
(B) Lymph node T cells from wild-type and
mutant transgenic mice were cultured with
I-Abm12-expressing APCs for 3 days, and the
expression of Fas ligand (FasL), Fas, E2F-1,
p73, Bcl-2, and Bcl-XL on V2-expressing
wild-type (blue histogram) and mutant (red
histogram) T cells were determined by flow
cytometry. The mean channel fluorescence
(MFI) of anti-FasL-stained wild-type and mu-
tant T cells were 50 and 23, respectively. 45%
of wild-type T cells express high levels of p73
compared to only 18% of mutant T lympho-
cytes.
(C) Wild-type (white bars) and mutant (black
bars) T cells were exposed to 	 irradiation
(1000 rads) or cultured with: etoposide (100
nM), staurosporine (10 nM), C2 or C6 cer-
amide (50 M), ionomycin (1 M), actinomy-
cin D (1 nM), PMA (100–50 ng/mL) plus iono-
mycin (0.1 M), and plate bound anti-CD3
(coated with 10 g/mL) plus soluble anti-Fas
MoAb Jo2 (10 g/mL). Twenty-four hours
later, apoptotic T cells were detected by
Annexin V staining and flow cytometry. The
data are representative of three experiments.
mutation in the TCR chain leads to a defect in the they either die or differentiate into memory cells. It is
still not completely understood how the  TCR controlsactivation of the NF-B signaling pathway.
these distinct T cells fates. Here, we report that mutation
of the transmembrane and cytoplamasmic domains ofCarma-1 and Bcl-10 Are Poorly Recruited
the TCR  chain causes a defect in apoptosis, but notto the Mutant TCR
Because Carma-1 and its binding partner Bcl-10 are in proliferation. This apoptotic defect is associated with
proximal TCR signaling intermediates of the NF-B sig- a disruption in the interaction between the mutant recep-
nal cascade (Jun and Goodnow, 2003; Thome, 2004), tor and Carma-1, which connects the surface TCR with
we examined the ability of the mutant TCR to colocalize the NF-B signaling pathway (Jun and Goodnow, 2003;
with Carma-1 by confocal microscopy (Figure 7A). The Thome, 2004). As a result, the mutant receptor is im-
images show that Carma-1 efficiently cocaps with CD3 paired in recruiting Bcl-10, in activating NF-B, and in
in wild-type, but not in mutant, T cells. Among stimulated inducing the expression of FasL, a gene whose tran-
T lymphocytes, which underwent CD3 capping, we ob- scription is dependent on NF-B induction (Kasibhatla
served Carma-1 cocapping in 82% of wild-type cells et al., 1999; Matsui et al., 1998, 2000; Teixeiro et al.,
but in only 15% of mutant T cells (p  4  1011). There- 1999; Wan and DeGregori, 2003). These data suggest
fore, the mutant receptor is inefficient in recruiting that the  chain transmembrane and cytoplasmic do-
Carma-1. As Carma-1 recruits Bcl-10 to the membrane mains are important for AICD.
upon TCR engagement (Gaide et al., 2002), the cocap- Although T lymphocytes expressing the mutant recep-
ping of CD3 and Bcl-10 in both types of T cells was tor accumulate during a proliferative response, they
examined. Similarly, Bcl-10 fails to colocalize with the don’t show a decrease in the commitment time to prolif-
TCR/CD3 complex in mutant T cells (Figure 7B). Cross- erate (Figure 2). Moreover, mutant and wild-type cells
linking the TCR with anti-V antibody generated similar are similar in terms of IL-2 secretion and IL-2R (CD25)
results (Supplemental Figure S2). This defect may be expression (Figures 2 and 5), and they undergo cell divi-
limited to Carma-1, since other raft-associated proteins sion with equivalent kinetics (Figures 3 and 5). Finally,
such as Lck are recruited to the mutant TCR (Figure 7C). early activation events such as CD69 expression (Figure
Taken together, these data suggest that the decrease in 2) and signaling events such as CD3/ chain phosphor-
NF-B signaling in mutant T cells is due to the inability ylation, Ca2 flux, and MAPK induction are unaltered in
of the mutant receptor to recruit Carma-1. mutant T cells (Figure 6). This indicates that several
signaling pathways and T cell responses remain unaf-
Discussion fected by this TCR mutation.
There is no obvious defect in the apoptotic machinery
per se, since a wide variety of pharmacological agentsUpon TCR engagement, T cells become activated, ac-
quire effector functions, and proliferate; subsequently, and anti-Fas antibodies readily induce apoptosis in mu-
TCR Constant Domains Control AICD
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Figure 5. TM/Cyto Mutant T Cells Are Defective in AICD Across a Broad Range of Ligand Concentrations
(A) Wild-type and TM/Cyto mutant T cells were stained with CFSE and stimulated with I-Abm12 spleen APCs pulsed with the class II-blocking
anti-I-A bm12 antibody, 3JP to provide a titration of antigen dose. Their division profile for day 3 poststimulation is shown. Wild-type profiles
are shown in blue, and mutant profiles are shown in red. The number in each plot reflects the dose of blocking antibody in g/ml. These data
are representative in that the CSFE profiles of wild-type and mutant T cells are equivalent at all doses of the I-Abm12-blocking mAb used.
(B) The T cell division indices of the cultures shown in (A) were determined (see Experimental Procedures) and shown as a plot of antigen
dose versus division index. Wild-type is represented by (O), and TM/Cyto mutant by ().
(C) The same population of T cells as in (A) was tested for IL-2 secretion and is plotted as antigen dose versus MFI of secreted IL-2-positive
cells. IL-2 was measure with a capture assay (see Experimental Procedures).
(D) For measurement of AICD, wild-type and mutant T cells were stimulated with irradiated I-Abm12 spleen cells for 3 days to induce Fas
expression and restimulated with fresh I-Abm12 splenocytes in the presence of anti-I-Abm12-blocking antibody, 3JP, at the doses indicated. After
36 hrs, AICD was assessed by Annexin V staining (day 5 postinitial stimulation). The results are plotted as antigen dose versus percentage
Annexin V T cells. In all experiments, wild-type and mutant T cells are stimulated with B6 spleen (I-Ab) as a negative control. Data is
representative of at least three experiments.
tant cells (Figure 4). The accumulation of cells seems FasL promoter (Hsu et al., 1999; Kasibhatla et al., 1999;
Matsui et al., 1998, 2000; Teixeiro et al., 1999).to be due to a defect in the mutant TCR’s ability to
induce AICD (Figures 4 and 5). While both types of T cells We have also studied the contribution of other prosur-
vival factors to the apoptosis-resistant phenotype. Nei-express equivalent levels of Fas, mutant cells exhibit a
significant impairment in the expression of FasL (Figure ther Bcl-2 nor Bcl-XL expression are altered in mutant
T cells (Figure 4B). On the other hand, the expression4). Furthermore, apoptosis is reduced to similar levels
in stimulated wild-type and mutant T cells in the pres- of E2F-1 and p73, two transcription factors linked to
AICD (Lissy et al., 2000), is impaired in stimulated mutantence of FasL blocking reagents (data not shown). Taken
together, the accumulation of mutant T cells seems to T cells (Figure 4). p73 is positively regulated by E2F-1
and antagonized by NF-B (Irwin et al., 2000; Wan andbe a consequence of the mutant receptor’s inability to
induce normal levels of FasL and, as a result, to properly DeGregori, 2003). Interestingly, mutant T cells display a
decrease in p73 expression in spite of a decrease in NF-induce FasL-mediated cell death (Figure 4). The impair-
ment of FasL expression in TM/Cyto mutant T cells B activation. The decrease in E2F-1 expression may
interfere with p73 induction, regardless of the extent ofcorrelates with the observed NF-B signaling defect
(Figure 6D). We and others have previously demon- NF-B activation. Nevertheless, considering the accu-
mulation of T cells seen in FasL-deficient mice (Cohenstrated the relevance of NF-B in the upregulation of
FasL and the presence of NF-B binding sites in the and Eisenberg, 1991; Russell et al., 1993), it is likely
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Figure 6. Mutant T Cells Show a Defect in TCR-Mediated NF-B Signaling
(A) CD3 and  chain phosphorylation was measured in stimulated T cells by Western blotting with the antiphosphotyrosine mAb 4G10. Blots
were reprobed for CD3 and  to confirm the identity of the phosphoproteins.  protein and -tubulin are shown as loading controls.
(B) Ca2 mobilization upon TCR/CD3 stimulation was measured by Fura-2 fluorescence and is shown as a ratio of the fluorescence 340 nm/
380 nm.
(C) Phosphorylation of JNK and ERK was measured in stimulated T cells by Western blotting with antiphospho JNK or antiphospho ERK
antibodies. Blots were reprobed for -tubulin and ERK as loading controls. Densitometric intensity of phospho-JNK relative to nonstimulated
cells is corrected for loading and shown below the panel.
(D) Phosphorylation of IB was analyzed as in (C) with antiphospho IB antibodies. The degradation of IB was measured by Western
blot, and the densitometry of IB was performed as in (C).
that the decrease in FasL expression makes a major Although both Carma-1 deficiency and the TM/Cyto
mutation affects IB degradation and NF-B activationcontribution to the T cell phenotype seen in TM/Cyto
mutant mice. (Egawa et al., 2003; Gaide et al., 2002), there are striking
phenotypic differences between mutant TCR- andCarma-1 and Bcl-10 are TCR-proximal signaling
adapters required for NF-B activation (Gaide et al., Carma-1-deficient mice. T cells lacking Carma-1 fail to
proliferate and secrete IL-2 upon TCR/CD3 stimulation,2002; Hara et al., 2003; Jun et al., 2003; Newton and
Dixit, 2003; Pomerantz et al., 2002; Ruland et al., 2001; whereas T cells expressing the mutant receptor prolifer-
ate and secrete IL-2 normally (Figures 2 and 5). Carma-Wang et al., 2002). Upon TCR stimulation, the mutant
TCR is deficient in activating the NF-B pathway be- 1-deficient T cells show a total blockade in NF-B activa-
tion (Egawa et al., 2003; Hara et al., 2003; Pomerantz etcause of its poor interaction with Carma-1 (Figure 7).
As a consequence, Bcl-10 is inefficiently recruited to al., 2002; Wang et al., 2002), whereas the TM/Cyto
mutant T cells only show a partial defect in NF-B signal-the plasma membrane (Figure 7). Carma-1 association
to lipid rafts is not affected in mutant T cells (data not ing. There is residual phosphorylation of IB at 1 and
5 min of stimulation, which apparently leads to the delayshown). Furthermore, other lipid raft-associated pro-
teins, such as Lck, colocalized normally with the mutant in IB degradation (Figure 6D). This delay correlates
with the delayed cocapping kinetics of CD3 to Bcl-10TCR (Figure 7). While Zap-70 inhibition does not lead to
a defect in TCR/Bcl-10 association, disruption of lipid in mutant cells (data not shown). In addition, mutant
T cells never fully recover their ability to colocalize thisrafts with methyl--cyclodextran (MCD) impairs the re-
cruitment of Bcl-10 to the TCR (data not shown). This adaptor (Supplemental Figure S3). Even after 1 week in
culture with antigenic APCs, mutant T cells still demon-suggests that Carma-1 requires both the TCR trans-
membrane and cytoplasmic domains as well as lipid strate a defect in Bcl-10 recruitment to the TCR and a
subsequent inability to induce AICD (Figures 4 and 5;rafts to recruit NF-B signaling intermediates to the
membrane (Che et al., 2004; Wang et al., 2004). data not shown).
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cell division and IL-2 expression, but might not be suffi-
cient for FasL induction. It is also possible that the tran-
scriptional requirements for the FasL gene require an
earlier, stronger, or more sustained activation of NF-
B. Along this line, mutation of NF-B sites in the IL-2
promoter are less deleterious than mutations of other
transcription factor binding sites for IL-2 expression
(Crabtree and Clipstone, 1994; Jain et al., 1995). In the
case of FasL, several reports have attributed a major
role for NF-B in FasL induction (Hsu et al., 1999; Matsui
et al., 1998, 2000). Taken together, this could explain
how the alteration observed in NF-B signaling leads to
a specific defect in AICD in mutant T cells.
The TM/Cyto mutant TCR is able to discriminate cell
division and IL-2 secretion from AICD (Figure 5). Several
studies support the idea that different T cell functions
are selectively induced based on quantitative differ-
ences in the level or duration of TCR signaling (Itoh and
Germain, 1997; Valitutti et al., 1996). Therefore, we have
considered whether differences in ligand affinity or
blunted signals by the mutant TCR could explain the
defect in AICD. This is likely not the case. First, in trans-
genic mice expressing a class I MHC-restricted TCR
with the same TM/Cyto mutation, no significant differ-
ences in TCR/pMHC affinity were found between the
wild-type and mutant TCR (Supplemental Figure S4).
Second, under conditions of titrated antigen availability,
wild-type and mutant T cells show an equivalent degree
of proliferation and IL-2 secretion at all antigen doses
(Figure 5). In contrast, a significantly lower fraction of
mutant cells underwent AICD than did wild-type T cells
at all antigen doses and these differences were main-
tained over time (Figure 5). Taken together, these data
suggest that the phenotype exhibited by mutant TCR is
not a consequence of a blunted TCR, which affect all
T cell responses.
Gene expression requires a coordinated activation of
transcription factors. This may be particularly true for
FasL, since a delay in NF-B signaling leads to a poor
induction of this death ligand. Carma-1, through its as-
sociation with the TCR, plays a central role in synchro-
nizing the induction of several signaling cascades lead-Figure 7. TM/Cyto Mutant T Cells Are Impaired in Recruiting
ing to AICD.Carma-1 and Bcl-10 to the TCR
(A) Lymph node T cells from wild-type or mutant mice were incu-
Experimental Proceduresbated with the anti-CD3 mAb 2C11 for 15 min. on ice followed by
incubation with an Alexa488 (green)-conjugated, secondary anti-
DNA Constructs, Viral Vectors, T Cell Hybridomas,hamster antiserum for 20 min at 0C (unstimulated) or at 37C (stimu-
and Cytokine Assayslated). After fixation and permeabilization, the samples were stained
cDNA constructs, viral vectors, and hybridoma lines have been de-with a polyclonal rabbit anti-Carma-1 serum followed by staining
scribed (Backstrom et al., 1996). Transduction of cDNA encodingwith an Alexa555-labeled, secondary goat anti-rabbit sera (red). The
the wild-type  chain along with cDNAs for the wild-type or mutantlocalization of both proteins was analyzed by confocal microscopy.
 chains using retroviral vectors was carried out as described (Back-Images of a representative cell and a field of cells are shown.
strom et al., 1996). The measurement of IL-2 and IL-3 have been(B) Wild-type and mutant cells were stimulated and stained as in
described (Backstrom et al., 1996, 1997).(A), except that red now represents staining with polyclonal rabbit
antibodies for Bcl-10.
(C) Wild-type and mutant cells were stimulated for 5 min and stained Transgenic Mice
as in (A) with polyclonal rabbit Lck antibodies, visualized in red. Transgenic mice expressing the wild-type 3bbm74 receptor have
been described (Backstrom et al., 1998). cDNAs encoding the wild-
type  chain and the TM/Cyto mutant chain were cloned into the
pHSE3 expression vector and the relevant DNA fragments coin-It’s unclear how the impairment of NF-B signaling in
jected into C57BL/6 zygotes. Founders were repeatedly crossed tomutant T cells specifically affects FasL expression, while
B6.Rag-2/ mice to ensure that only the transgenic TCR is ex-other NF-B-dependent functions such as cell division
pressed in these animals. Two founder lines expressing the mutant
and IL-2 secretion remain unaltered. Activation of receptor were established and displayed a similar phenotype.
MAPKs (JNK and ERK) and Ca2 flux could possibly cDNAs encoding the wild-type and the TM/Cyto mutant  chains
were cloned into the pHSE3 expression vector, and the relevantovercome the partial NF-B defect leading to normal
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DNA fragments separately injected into C57BL/6 zygotes to gener- washed again, and analyzed by flow cytometry. Levels of IL-2 are
expressed as the median fluorescent intensity (MFI).ate  chain-only mice. Animal experiments were carried out ac-
cording to the cantonal and federal laws of Switzerland. Animal
protocols were approved by the cantonal veterinarian of Basel, Swit- Division Index Calculations
zerland. The division index was calculated by analyzing the CFSE profile of
the populations of interest with the Proliferation Platform of FlowJo
Antibodies and Reagents FACS Analysis Software (Tree Star, Inc., Ashland, OR). The division
Monoclonal antibodies recognizing V2 (B20.1), CD4 (H129.19 or index represents the average number of divisions that a cell present
RM4-5), CD69 (H1.2F3), CD25 (PC6), CD5 (53-7.3), CD2 (RM2-5), in the starting population has undergone. The division index is (pro-
CD62L (MEL-14), Fas (Jo2), Fas ligand (MFL3), I-Abm12 (M5/114 and liferation index)(%divided) where the proliferation index is the aver-
3JP), and CD28 (37.51) were purchased from PharMingen. The 2C11 age number of divisions that those divided cells underwent, and
mAb was kindly provided by J. Bluestone. Antisera specific for p73 the %divided is the percentage of the cells of the original sample
(H-79) and E2F-1 (C-20) were purchased from Santa Cruz. The fol- that divided.
lowing antibodies were used for immunoblotting: antisera specific
for , CD3	, and CD3 (Backstrom et al., 1998); polyclonal rabbit
Confocal Microscopy
anti-IB (Santa Cruz Biotechnology, Inc.); polyclonal rabbit anti-
Lymph node T cells (0.25  106 cells) were washed in DMEM and
phospho-IB (Cell Signaling, Inc.); antiphospho-ERK (Cell Signal-
incubated on ice for 15 min with anti-CD3 mAb (2C11 10 g/mL).
ing, Inc.); antiphospho-JNK mAb (Santa Cruz Biotechnology, Inc.);
Cells were washed and incubated at 37C or 0C with conjugated
anti-ERK2 (Santa Cruz Biotechnology, Inc.); anti-phosphotyrosine
Alexa488 polyclonal goat anti-hamster antibodies (Molecular
mAb and 4G10 (Upstate Biotechnology); and anti- tubulin (SIGMA)
Probes) in DMEM/15 mM HEPES for 20 min. Stimulation was
mAb. Annexin V was purchased from Pharmingen. SEB was pur-
stopped with ice-cold PBS. Cells were then spun onto TESPA
chased from Toxin Technologies, and CFSE (C-1157) was pur-
(Sigma)-coated coverslips, fixed in PBS/3% paraformaldehyde for
chased from Molecular Probes. Alexa- and peroxidase-conjugated
30 min at room temperature, permeabilized for 5 min with 0.1% NP-
antibodies were purchased from Molecular Probes and Jackson
40/PBS on ice, incubated with blocking buffer (PBS/3% BSA), and
Immunosearch laboratories, respectively. Actinomycin D, C6-cer-
stained first, with rabbit antisera specific for Carma-1 (AL220) or
amide, etoposide, ionomycin, staurosporine, and Methyl--cyclo-
Bcl-10 (Santa Cruz Bioetch., Inc.) or Lck (Cell Signaling, Inc.) and
dextrin (MCD) were purchased from Sigma-Aldrich Chemicals.
second, with conjugated Alexa555 polyclonal goat anti-rabbit anti-
ZAP-70 inhibitor (ZAP-70 INHIBITOR-1) was kindly provided by
bodies (Molecular Probes) in PBS/1% BSA. After washing with PBS
G. Zenke (Novartis, AG, Basel, Switzerland).
and 0.1 PBS, the samples were mounted in FLUORSAVE reagent
(Calbiochem) and examined by confocal microscopy with a Carl
T Cell Stimulation and Flow Cytometry ZEISS confocal microscope and the LSM510 META software (Carl
Mixed leukocyte reactions between transgenic T cells and APCs Zeiss, Oberkochen, Germany).
were carried out as described (Backstrom et al., 1998). Flow cytome-
try was performed on a FACSCalibur flow cytometer (Becton Dickin-
Western Blottingson), and the data were analyzed with CellQuest software (Becton
5–10  106 cells for each time point in DMEM/15 mM HEPES (pHDickinson) or FlowJo FACS Analysis Software (Tree Star, Inc., Ash-
7.5) were incubated on ice with 10 g/ml anti-CD3 and 5 g/mlland, OR). The p73 and E2F-1 proteins were detected by intracellular
CD28 for 15 min, followed by incubation with polyclonal goat anti-staining with the Cytofix/Cytoperm intracellular staining kit (Phar-
hamster antibodies at 37C for different times of stimulation. CellMingen) to fix and permeabilize cells, primary rabbit antisera specific
pellets were lysed in lysis buffer (20 mM HEPES [pH 7.5], 1 mMfor the p73 and E2F-1 proteins (Santa Cruz Biotechnology, Inc.),
EGTA, 1% NP-40, 2.5 mM MgCl2, 1 mM dithiothreitol, 1 mM PMSF,and FITC-labeled goat anti-rabbit Ig antisera (PharMingen) as a
2 g/ml aprotinin, 2 g/ml leupeptin, 2 g/ml pepstatin A, 40 mMsecondary staining reagent. Induction of apoptosis with anti-Fas
-glycerophosphate, and 2 mM sodium orthovanadate) for 30 minwas performed in T cells that were previously stimulated with antigen
on ice. Cell lysates were subjected to SDS-PAGE under reducingto induced Fas expression. Then, the T cells were stimulated with the
conditions and transferred to a nitrocellulose membrane. The mem-anti-Fas mAb, Jo2, and additional TCR stimulation (2C11 10 g/mL
brane was blocked with 10% w/v skim milk in TBS-T (Tris Buffercoated to plate) to initiate apoptosis as previously described (Mup-
Saline plus 0.1% Tween 20) and incubated with specific antibodiespidi and Siegel, 2004; Wong et al., 1997).
according to the manufacturer’s instructions. After washing with
TBS-T, the membranes were incubated with peroxidase-labeled
Calcium Mobilization goat anti-mouse, anti-hamster, or anti-rabbit-IgG for 1h at room
For the Ca2 flux experiments, lymph node T cells were washed in temperature, and the proteins were visualized with ECL detection
Krebs buffer with 2% FCS and loaded with 5 g/ml Fura-AM (Sigma) reagent (Amersham Corp.). Quantification of bands was performed
for 30 min at 37C in the dark. Flux was induced by TCR crosslinking with a densitometer (Alphainnotech, San Leandro, CA); signals were
with the anti-CD3 mAb 2C11 and goat anti-hamster and measured normalized to a protein (-tubulin) serving as a loading control and
by a Perkin Elmer fluorimeter LS50. compared to unstimulated samples. For the detection of  and CD3
chain phosphorylation, the mAb antiphosphotyrosine 4G10 was
used (Upstate Biotechnology). The blot was then reprobed with anti-CFSE Labeling and Adoptive Transfer of Transgenic T Cells
CD3- and anti--specific antibodies (Backstrom et al., 1998) toLymph node T cells (2  107 cells/ml) were labeled in 0.5 M CFSE
confirm the identity of the phosphoproteins and with anti--tubulinin PBS for 8 min at room temperature. Labeling was terminated by
as a loading control.adding an equal volume of FCS and pelleting the cells by centrifuga-
tion. Cells were subsequently washed twice in medium containing
10% FCS and resuspended in PBS before intravenous (i.v.) injection. Acknowledgments
This work was supported by fellowships from the Fundacio´n Ramo´nIL-2 Secretion Assays
For determination of IL-2 secretion, T cells were stimulated with Areces, Madrid, Spain (E.T.), The Cancer Research Institute, USA
(M.A.D.), Ruth L. Kirschenstein National Research Service Awardirradiated I-Abm12 spleen cells at a ratio of 4 APC per T cell with the
Mouse IL-2 Secretion Assay Detection Kit (Miltenyi Biotec GmbH, from NCI and NIH (A.G.S.), and grants from the Swiss National Sci-
ence Foundation, Hoffmann La Roche, Ltd., Novartis, AG, the Minis-Bergisch Gladbach, Germany) following manufacturer’s instruc-
tions. Briefly, cells were washed two times in PBS  0.5% BSA and terio de Ciencia y Tecnologı´a, BMC2002-02644 (R.B.), and from
the Swiss Cancer League (OCS 01168-09-2001) (M.T.). We thank J.2 mM EDTA and stained on ice with the bispecific IL-2 catch reagent.
The cells were washed twice then incubated in RPMI 1640  5% Sprent, T. Ba¨ckstro¨m, and H. von Boehmer for interesting discus-
sions; S. Stotz for generating the TM/Cyto; U. Mu¨ller for generatingmouse serum at 37C for 45 min. This was followed by two washes
and incubation with the allophycorethrin-labeled -IL-2 reagent, transgenic mice; S. Treves for assistance with the Ca2 flux; B.
TCR Constant Domains Control AICD
525
Favier for technical advice; and G. DeLibero, D. Gil, and G. Werlen lated hierarchical T cell antigen receptor signaling thresholds and
intraclonal heterogeneity for individual cytokine responses of CD4for critical review of the manuscript.
T cells. J. Exp. Med. 186, 757–766.
Received: February 26, 2004 Jain, J., Loh, C., and Rao, A. (1995). Transcriptional regulation of
Revised: July 19, 2004 the IL-2 gene. Curr. Opin. Immunol. 7, 333–342.
Accepted: August 18, 2004 Ju, S.T., Panka, D.J., Cui, H., Ettinger, R., el-Khatib, M., Sherr, D.H.,
Published: October 19, 2004 Stanger, B.Z., and Marshak-Rothstein, A. (1995). Fas(CD95)/FasL
interactions required for programmed cell death after T-cell activa-
References tion. Nature 373, 444–448.
Jun, J.E., and Goodnow, C.C. (2003). Scaffolding of antigen recep-
Backstrom, B.T., Milia, E., Peter, A., Jaureguiberry, B., Baldari, C.T., tors for immunogenic versus tolerogenic signaling. Nat. Immunol.
and Palmer, E. (1996). A motif within the T cell receptor alpha chain 4, 1057–1064.
constant region connecting peptide domain controls antigen re-
Jun, J.E., Wilson, L.E., Vinuesa, C.G., Lesage, S., Blery, M., Miosge,sponsiveness. Immunity 5, 437–447.
L.A., Cook, M.C., Kucharska, E.M., Hara, H., Penninger, J.M., et
Backstrom, B.T., Hausmann, B.T., and Palmer, E. (1997). Signaling al. (2003). Identifying the MAGUK protein CARMA-1 as a central
efficiency of the T cell receptor controlled by a single amino acid regulator of humoral immune responses and atopy by genome-wide
in the beta chain constant region. J. Exp. Med. 186, 1933–1938. mouse mutagenesis. Immunity 18, 751–762.
Backstrom, B.T., Muller, U., Hausmann, B., and Palmer, E. (1998). Kasibhatla, S., Genestier, L., and Green, D.R. (1999). Regulation
Positive selection through a motif in the alpha beta T cell receptor. of fas-ligand expression during activation-induced cell death in T
Science 281, 835–838. lymphocytes via nuclear factor kappaB. J. Biol. Chem. 274, 987–992.
Boehme, S.A., and Lenardo, M.J. (1993). Propriocidal apoptosis of Kavurma, M.M., and Khachigian, L.M. (2003). Signaling and tran-
mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. scriptional control of Fas ligand gene expression. Cell Death Differ.
Immunol. 23, 1552–1560. 10, 36–44.
Che, T., You, Y., Wang, D., Tanner, M.J., Dixit, V.M., and Lin, X. Kurts, C., Carbone, F.R., Barnden, M., Blanas, E., Allison, J., Heath,
(2004). MALT1/paracaspase is a signaling component downstream W.R., and Miller, J.F. (1997). CD4 T cell help impairs CD8 T cell
of CARMA1 and mediates T cell receptor-induced NF-kappaB acti- deletion induced by cross-presentation of self-antigens and favors
vation. J. Biol. Chem. 279, 15870–15876. autoimmunity. J. Exp. Med. 186, 2057–2062.
Cohen, P.L., and Eisenberg, R.A. (1991). Lpr and gld: single gene Lenardo, M., Chan, K.M., Hornung, F., McFarland, H., Siegel, R.,
models of systemic autoimmunity and lymphoproliferative disease. Wang, J., and Zheng, L. (1999). Mature T lymphocyte apoptosis—
Annu. Rev. Immunol. 9, 243–269. immune regulation in a dynamic and unpredictable antigenic envi-
Combadiere, B., Sousa, C.R.E., Germain, R.N., and Lenardo, M.J. ronment. Annu. Rev. Immunol. 17, 221–253.
(1998). Selective induction of apoptosis in mature T lymphocytes Lissy, N.A., Davis, P.K., Irwin, M., Kaelin, W.G., and Dowdy, S.F.
by variant T cell receptor ligands. J. Exp. Med. 187, 349–355. (2000). A common E2F-1 and p73 pathway mediates cell death
induced by TCR activation. Nature 407, 642–645.Crabtree, G.R., and Clipstone, N.A. (1994). Signal transmission be-
tween the plasma membrane and nucleus of T lymphocytes. Annu. Marsden, V.S., and Strasser, A. (2003). Control of apoptosis in the
Rev. Biochem. 63, 1045–1083. immune system: Bcl-2, BH3-only proteins and more. Annu. Rev.
Immunol. 21, 71–105.DiGiusto, D.L., and Palmer, E. (1994). An analysis of sequence varia-
tion in the beta chain framework and complementarity determining Matsui, K., Fine, A., Zhu, B., Marshak-Rothstein, A., and Ju, S.T.
regions of an allo-reactive T cell receptor. Mol. Immunol. 31, (1998). Identification of two NF-kappa B sites in mouse CD95 ligand
693–699. (Fas ligand) promoter: functional analysis in T cell hybridoma. J.
Immunol. 161, 3469–3473.Egawa, T., Albrecht, B., Favier, B., Sunshine, M.J., Mirchandani, K.,
O’Brien, W., Thome, M., and Littman, D.R. (2003). Requirement for Matsui, K., Xiao, S., Fine, A., and Ju, S.T. (2000). Role of activator
CARMA1 in antigen receptor-induced NF-kappa B activation and protein-1 in TCR-mediated regulation of the murine fasl promoter.
lymphocyte proliferation. Curr. Biol. 13, 1252–1258. J. Immunol. 164, 3002–3008.
Gaide, O., Favier, B., Legler, D.F., Bonnet, D., Brissoni, B., Valitutti, Muppidi, J.R., and Siegel, R.M. (2004). Ligand-independent redistri-
S., Bron, C., Tschopp, J., and Thome, M. (2002). CARMA1 is a critical bution of Fas (CD95) into lipid rafts mediates clonotypic T cell death.
lipid raft-associated regulator of TCR-induced NF-kappa B activa- Nat. Immunol. 5, 182–189.
tion. Nat. Immunol. 3, 836–843. Newton, K., and Dixit, V.M. (2003). Mice lacking the CARD of
Green, D.R., Droin, N., and Pinkoski, M. (2003). Activation-induced CARMA1 exhibit defective B lymphocyte development and impaired
cell death in T cells. Immunol. Rev. 193, 70–81. proliferation of their B and T lymphocytes. Curr. Biol. 13, 1247–1251.
Hara, H., Wada, T., Bakal, C., Kozieradzki, I., Suzuki, S., Suzuki, N., Petersen, T.R., Gulland, S., Bettelli, E., Kuchroo, V., Palmer, E., and
Nghiem, M., Griffiths, E.K., Krawczyk, C., Bauer, B., et al. (2003). Backstrom, B.T. (2004). A chimeric T cell receptor with super-signal-
The MAGUK family protein CARD11 is essential for lymphocyte acti- ing properties. Int. Immunol. 16, 889–894.
vation. Immunity 18, 763–775. Pomerantz, J.L., Denny, E.M., and Baltimore, D. (2002). CARD11
Hsu, S.C., Gavrilin, M.A., Lee, H.H., Wu, C.C., Han, S.H., and Lai, mediates factor-specific activation of NF-kappaB by the T cell re-
M.Z. (1999). NF-kappa B-dependent Fas ligand expression. Eur. J. ceptor complex. EMBO J. 21, 5184–5194.
Immunol. 29, 2948–2956. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin,
Iezzi, G., Scotet, E., Scheidegger, D., and Lanzavecchia, A. (1999). K.M., Fischer, A., and de Villartay, J.P. (1995). Mutations in Fas
The interplay between the duration of TCR and cytokine signaling associated with human lymphoproliferative syndrome and autoim-
determines T cell polarization. Eur. J. Immunol. 29, 4092–4101. munity. Science 268, 1347–1349.
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Rodriguez-Tarduchy, G., Sahuquillo, A.G., Alarcon, B., and Bragado,
Steiner, V., Bodmer, J.L., Schroter, M., Burns, K., Mattmann, C., et R. (1996). Apoptosis but not other activation events is inhibited by
al. (1997). Inhibition of death receptor signals by cellular FLIP. Nature a mutation in the transmembrane domain of T cell receptor beta
388, 190–195. that impairs CD3zeta association. J. Biol. Chem. 271, 30417–30425.
Irwin, M., Marin, M.C., Phillips, A.C., Seelan, R.S., Smith, D.I., Liu, Rothwarf, D.M., and Karin, M. (1999). The NF-kappa B activation
W., Flores, E.R., Tsai, K.Y., Jacks, T., Vousden, K.H., and Kaelin, pathway: a paradigm in information transfer from membrane to nu-
W.G. (2000). Role for the p53 homologue p73 in E2F-1-induced cleus. Sci STKE 1999, RE1.
apoptosis. Nature 407, 645–648. Ruland, J., Duncan, G.S., Elia, A., Barrantes, I.D., Nguyen, L., Plyte,
S., Millar, D.G., Bouchard, D., Wakeham, A., Ohashi, P.S., and Mak,Itoh, Y., and Germain, R.N. (1997). Single cell analysis reveals regu-
Immunity
526
T.W. (2001). Bcl10 is a positive regulator of antigen receptor-induced
activation of NF-kappa B and neural tube closure. Cell 104, 33–42.
Russell, J.H., Rush, B., Weaver, C., and Wang, R. (1993). Mature
T cells of autoimmune lpr/lpr mice have a defect in antigen-stimu-
lated suicide. Proc. Natl. Acad. Sci. USA 90, 4409–4413.
Suda, T., Tanaka, M., Miwa, K., and Nagata, S. (1996). Apoptosis of
mouse naive T cells induced by recombinant soluble Fas ligand and
activation-induced resistance to Fas ligand. J. Immunol. 157, 3918–
3924.
Sytwu, H.K., Liblau, R.S., and McDevitt, H.O. (1996). The roles of
Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell
death in T cell receptor transgenic mice. Immunity 5, 17–30.
Teixeiro, E., Garcia-Sahuquillo, A., Alarcon, B., and Bragado, R.
(1999). Apoptosis-resistant T cells have a deficiency in NF-chi
B-mediated induction of Fas ligand transcription. Eur. J. Immunol.
29, 745–754.
Thome, M. (2004). CARMA1, BCL-10 and MALT1 in lymphocyte
development and activation. Nat. Rev. Immunol. 4, 348–359.
Valitutti, S., Muller, S., Dessing, M., and Lanzavecchia, A. (1996).
Different responses are elicited in cytotoxic T lymphocytes by differ-
ent levels of T cell receptor occupancy. J. Exp. Med. 183, 1917–1921.
Wan, Y.S.Y., and DeGregori, J. (2003). The survival of antigen-stimu-
lated T cells requires NF kappa B-mediated inhibition of p73 expres-
sion. Immunity 18, 331–342.
Wang, D., You, Y., Case, S.M., McAllister-Lucas, L.M., Wang, L.,
DiStefano, P.S., Nunez, G., Bertin, J., and Lin, X. (2002). A require-
ment for CARMA1 in TCR-induced NF-kappa B activation. Nat. Im-
munol. 3, 830–835.
Wang, D., Matsumoto, R., You, Y., Che, T., Lin, X.Y., Gaffen, S.L.,
and Lin, X. (2004). CD3/CD28 costimulation-induced NF-kappaB
activation is mediated by recruitment of protein kinase C-theta,
Bcl10, and IkappaB kinase beta to the immunological synapse
through CARMA1. Mol. Cell. Biol. 24, 164–171.
Wong, B., Arron, J., and Choi, Y. (1997). T cell receptor signals
enhance susceptibility to Fas-mediated apoptosis. J. Exp. Med.
186, 1939–1944.
Zhou, H., Wertz, I., O’Rourke, K., Ultsch, M., Seshagiri, S., Eby, M.,
Xiao, W., and Dixit, V.M. (2004). Bcl10 activates the NF-kappaB
pathway through ubiquitination of NEMO. Nature 427, 167–171.
